The drug, intended for adult patients with moderate-to-severe systemic lupus erythematosus, is the only new therapy approved for SLE in more than a decade.
Arcturus Therapeutics and its Vietnam partner Vinbiocare will take ARCT-154, a next-generation Arcturus vaccine targeting SARS-CoV-2 variants of concern, into a Phase 1/2/3 trial. The companies will also establish a vaccine manufacturing centre in Vietnam....
With Scancell taking its DNA-based COVID-19 vaccine tech into clinical trials this year, it is already focusing its attention on the tech’s potential to be used as a needle-free booster shot to address Variants of Concern.
The mRNA vaccine developed by Pfizer and BioNTech generates far higher levels of antibodies against the coronavirus than Sinovac’s inactivated virus prophylactic, according to a study.
Data presented by Prothena at AAIC on two of its Alzheimer’s disease programs suggests PRX012, its next generation anti-amyloid beta (Aβ) antibody, can clear two types of Aβ plaque in brain tissue, and that its AD vaccine program can simultaneously target...
A study of more than a million vaccinated people has found 'similar safety profiles' for the AstraZeneca and Pfizer/BioNTech vaccines: adding the incidence of rare blood clots was far higher among people with COVID-19 than those who had received...
AC Immune will acquire Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), which includes a vaccine candidate for the treatment of Parkinson’s disease.
BioNTech aims to develop the first mRNA-based malaria vaccine, hoping to reach clinical trials by 2022. Meanwhile, it is also exploring possibilities to set up mRNA manufacturing facilities on the African continent – which could potentially be used for...
Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally
